REG - SkinBioTherapeutics - Issue of Equity and Total Voting Rights

SkinbiotherapeuticsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST4968Pa&default-theme=true

RNS Number : 4968P  SkinBioTherapeutics PLC  20 January 2026

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Issue of Equity and Total Voting Rights

 

20 January 2026 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the
life science business focused on skin health, announces that it has issued,
conditional on admission, 129,736 new ordinary shares of 1 pence each in the
capital of the Company ("Ordinary Shares"), pursuant to the share options
agreement entered into by the Company and a previous employee upon IPO.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares
in issue and application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the new
Ordinary Shares commence, at 8:00 a.m. on 22 January 2026.

 

Total Voting Rights

 

Following Admission, the Company will have 258,779,463 Ordinary Shares in
issue. This figure of 258,779,463 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  +44 (0) 191 495 7325
 Stuart J. Ashman, CEO

Emily Bertram, CFO
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting (financial press)                        +44 (0) 20 7390 0230
 Melanie Toyne-Sewell

Rozi Morris                                             SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUCGGUPQGMB



            Copyright 2019 Regulatory News Service, all rights reserved